Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs YourHealthRx

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and YourHealthRx head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 209 · Grade C

YourHealthRx

Visit YourHealthRx Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 68 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make YourHealthRx a bad call — it's best for readers who want to understand prepaid supply options and the separate platform, clinician and pharmacy roles. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
36
Supply Reliability
95
80
Transparency
90
48
Access Breadth
93
96
Clinical Oversight
92
88
Track Record
88
77
CoreAge RxBrief Score 94 · 68YourHealthRx

Price, coverage & the tracker

CoreAge RxYourHealthRx
Brief Score94/100 (A)68/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

$170/month injection plan

Injection alternatives: $450 upfront for three months or $840 upfront for six ($140/month equivalent).

Oral tablets are separate: $200 monthly, $540 for three months or $1,020 for six. Clinical/pharmacy policies and state eligibility differ.

Full price details

Compounded semaglutide injection advertised at $170 monthly, $450 upfront for three months or $840 upfront for six months; oral tablets have separate prices; earlier listing: From $170/mo (compounded)

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

$210/month injection plan

Injection alternatives: $600 upfront for three months or $1,140 upfront for six ($190/month equivalent).

Oral tablets are separate: $220 monthly, $570 for three months or $1,080 for six. Clinical/pharmacy policies and state eligibility differ.

Full price details

Compounded tirzepatide injection advertised at $210 monthly, $600 upfront for three months or $1,140 upfront for six months; oral tablets have separate prices; earlier listing: From $210/mo (compounded)

CoverageUS only; restrictions by state, confirmed at intakeWebsite expressly says clinical services and some formulations are not available in all states; confirm patient-location and product eligibility with the independent clinician.
Brand-name accessNot confirmedReviewed current offers are compounded tablets and injections; brand-name comparison articles do not establish branded fulfillment.
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

YourHealthRx: YourHealthRx separates monthly purchases from full prepaid supplies and distinguishes its coordination role from clinical and pharmacy services.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.